The response of immune cells in cardiac injury is divided into three continuous phases:
inflammation, proliferation and maturation. The kinetics of the inflammatory and proliferation …

The early and efficient assessment of cardiac safety liabilities is essential to confidently
advance novel drug candidates. This article discusses evolving mechanistically based …

Congenital heart defects constitute the most common human birth defect, however
understanding of how these disorders originate is limited by our ability to model the human …

The polymer polydimethylsiloxane (PDMS) is widely used to build microfluidic devices
compatible with cell culture. Whilst convenient in manufacture, PDMS has the disadvantage …

Drug discovery and development are hampered by high failure rates attributed to the
reliance on non-human animal models employed during safety and efficacy testing. A …

Since human embryonic stem cells were first differentiated to beating cardiomyocytes a
decade ago, interest in their potential applications has increased exponentially. This has …

Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

Background—Cardiotoxicity is a leading cause for drug attrition during pharmaceutical
development and has resulted in numerous preventable patient deaths. Incidents of adverse …

Cardiovascular disease is a leading cause of death worldwide. The limited capability of
heart tissue to regenerate has prompted methodological developments for creating de novo …

The engineering of 3-dimensional (3D) heart muscles has undergone exciting progress for
the past decade. Profound advances in human stem cell biology and technology, tissue …